Also known as: insulin human
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
A study of over 85,000 women found that insurance coverage and healthcare access significantly affect folic acid use, increasing preventable birth defect risks. The findings support fortification efforts, while a University of Houston initiative aims to address pharmacy access barriers.
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
The FDA approved Tzield for stage 3 type 1 diabetes, and the therapy was given to children in Canada for the first time. Research also advanced on engineered islets and stem-cell treatments.
China's 12th national Volume-Based Procurement round places RMB 60 billion across 65 drug varieties, accelerating generics and biosimilars substitution. Separately, Genialis launched BioBridge to help translate Chinese oncology trial results into Western development programs, as Chinese out-licensing hit $137.7 billion in 2025.
A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.
The global insulin drugs and delivery devices market is dominated by three manufacturers supplying roughly 90% of volume, with biosimilar entry slowly eroding this oligopoly. The market is projected to see continued growth driven by rising diabetes prevalence, while pricing pressure from biosimilars and government policies accelerates. In the Middle East, the recombinant human insulin market is projected to expand at a 6–8% CAGR through 2035.
FiberSense received CE marking for its optical CGM system with up to 28-day wear, while LifeScan partnered with i-SENS to launch the OneTouch Vita CGM and appointed a new CEO. Senseonics' year-long Eversense 365 implantable CGM is also detailed.
MiniMed completed its $538 million IPO as its separation from Medtronic advances, with shares trading on the Nasdaq. Medtronic submitted the next-generation MiniMed Flex insulin pump to the FDA and reported a 14.8% year-over-year revenue increase for its Diabetes business. The full separation is expected to be complete by the end of calendar year 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07746206 |
Local Application of Insulin Versus Hyaluronic Acid in Stage III Periodontitis |
RECRUITING | EARLY_PHASE1 |
| NCT07628556 |
Antidiabetic Medications and Risk of Cancer |
COMPLETED | |
| NCT07548996 |
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes |
RECRUITING | PHASE2/PHASE3 |
| NCT07494084 |
Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance |
NOT_YET_RECRUITING | PHASE4 |
| NCT07460336 |
Effects of Cofrogliptin on Beta-Cell Function in LADA Patients |
NOT_YET_RECRUITING | NA |
| NCT07432581 |
Topical Insulin Dressing on Management of Diabetic Foot Ulcers |
COMPLETED | NA |
| NCT07293715 |
Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) |
RECRUITING | PHASE4 |
| NCT07259564 |
A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) |
TERMINATED | PHASE2 |
| NCT06781775 |
GDM: Insulin with or Without Metformin? |
RECRUITING | PHASE4 |
| NCT06762314 |
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes |
RECRUITING | PHASE2 |
